Invokana · DIN 02425483 · 100 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Savings card: RxHelp ONE lists INVOKANA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Invokana · DIN 02425483
Manufacturer: Janssen Inc.; listing date 2015-07-29
Health Canada: Marketed since 2014-06-03 · brand INVOKANA · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 100 MG · company Janssen inc · schedule Prescription
Ministry pays: $0.7228 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02425483)
Source record
DIN 02425483: Invokana
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002055; group id 740; item number 1809; lccId None; manufacturer id JAN
Source form: Tab; strength: 100mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $2.8910; ministry $0.7228
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02425483
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91013
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564556 · $0.7228
Auro-Canagliflozin · DIN 02510367 · $0.7228
Jamp Canagliflozin · DIN 02543486 · $0.7228
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02425483
Shortage record checked October 6, 2026